tbuckley/cabot-search huggingface dataset:
Gene Expression Profiling in Down Syndrome Acute Lymphoblastic Leukemia Identifies Distinct Profiles Associated with CRLF2 Expression Status.
Authors: Karen R. Rabin, Jinhua Wang, Julia Meyer, Michael G. Loudin, Deepa Bhojwani, Debra Morrison, Meenakshi Devidas, Nyla A. Heerema, Andrew J. Carroll, Andrea Pession, Giuseppe Basso, Charles G. Mullighan, Stephen P Hunger, William L. Carroll
Journal: Blood (2009)
OS6.1 Molecular characterization of astroblastoma
Authors: M. Antonelli, D. Sturm, D. T. Jones, A. von Deimling, A. Korshunov, M. Kool, S. M. Pfister, F. Giangaspero, D. Capper
Journal: Neuro-Oncology (2016)

Astroblastoma is a rare brain tumor mainly defined by histological features of perivascular orientated glial cells with abundant eosinophilic cytoplasm and the presence of pericellular and vascular hyalinization as well as formation of pseudo-papillae. Molecular studies on this entity are scarce. Clinical courses range from benign to highly malignant. Recurrent MN1 gene fusions have recently been identified in a subset of CNS-PNET with overrepresentation of astroblastic histological features (designated CNS high-grade neuroepithelial tumor with MN1 alteration / HGNET- MN1 ). We here analyzed a large retrospective series of 37 tumors with histological features of astroblastoma by genome-wide DNA methylation profiling, copy number analysis, and targeted sequencing in a subset of cases. Unsupervised hierarchical clustering analysis of DNA methylation data together with a large number of established CNS tumor classes assigned astroblastomas to several molecular classes. The largest number shows high similarity to the HGNET MN1 group (20/37; 54% of cases). Remaining tumors molecularly resemble various ependymoma subgroups (4/37; 11%), glioblastoma subgroups (3/37; 8%), pleomorphic xanthoastrocytoma (3/38; 8%), CNS highgrade neuroepithelial tumor with BCOR alteration (2/37; 5%), or are non-classifiable (5/37; 14%). Histologically, tumors from the HGNET- MN1 group display more homogenous astroblastic features than the remaining fraction. Available clinical data of this group confirms female predominance, frequent superficial location, and may indicate a better prognosis compared to non-HGNET- MN1 CNS tumors with astroblastic features.
Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline
Authors: Monika Ferlitsch, Alan Moss, Cesare Hassan, Pradeep Bhandari, Jean-Marc Dumonceau, Gregorios Paspatis, Rodrigo Jover, Cord Langner, Maxime Bronzwaer, Kumanan Nalankilli, Paul Fockens, Rawi Hazzan, Ian Gralnek, Michael Gschwantler, Elisabeth Waldmann, Philip Jeschek, Daniela Penz, Denis Heresbach, Leon Moons, Arnaud Lemmers, Konstantina Paraskeva, Juergen Pohl, Thierry Ponchon, Jaroslaw Regula, Alessandro Repici, Matthew Rutter, Nicholas Burgess, Michael Bourke
Journal: Endoscopy (2017)

<b>1</b> ESGE recommends cold snare polypectomy (CSP) as the preferred technique for removal of diminutive polyps (size ≤ 5 mm). This technique has high rates of complete resection, adequate tissue sampling for histology, and low complication rates. (High quality evidence, strong recommendation.) <b>2</b> ESGE suggests CSP for sessile polyps 6 – 9 mm in size because of its superior safety profile, although evidence comparing efficacy with hot snare polypectomy (HSP) is lacking. (Moderate quality evidence, weak recommendation.) <b>3</b> ESGE suggests HSP (with or without submucosal injection) for removal of sessile polyps 10 – 19 mm in size. In most cases deep thermal injury is a potential risk and thus submucosal injection prior to HSP should be considered. (Low quality evidence, strong recommendation.) <b>4</b> ESGE recommends HSP for pedunculated polyps. To prevent bleeding in pedunculated colorectal polyps with head ≥ 20 mm or a stalk ≥ 10 mm in diameter, ESGE recommends pretreatment of the stalk with injection of dilute adrenaline and/or mechanical hemostasis. (Moderate quality evidence, strong recommendation.) <b>5</b> ESGE recommends that the goals of endoscopic mucosal resection (EMR) are to achieve a completely snare-resected lesion in the safest minimum number of pieces, with adequate margins and without need for adjunctive ablative techniques. (Low quality evidence; strong recommendation.) <b>6</b> ESGE recommends careful lesion assessment prior to EMR to identify features suggestive of poor outcome. Features associated with incomplete resection or recurrence include lesion size > 40 mm, ileocecal valve location, prior failed attempts at resection, and size, morphology, site, and access (SMSA) level 4. (Moderate quality evidence; strong recommendation.) <b>7</b> For intraprocedural bleeding, ESGE recommends endoscopic coagulation (snare-tip soft coagulation or coagulating forceps) or mechanical therapy, with or without the combined use of dilute adrenaline injection. (Low quality evidence, strong recommendation.) An algorithm of polypectomy recommendations according to shape and size of polyps is given (<xref idref="FI15335-1">Fig. 1</xref>).
Novel Functions for a Fibrinolytic Pathway in Controlling the Stem Cell Niche.
Authors: Haruyo Akiyama, Leif R. Lund, Yohei Morita, Hiromitsu Nakauchi, Hideoki Ogawa, Ko Okumura, Keld Dano, Zena Werb, Beate Heissig, Koichi Hattori
Journal: Blood (2006)
Evaluation of two different schedules of bevacizumab (BEV) with oxaliplatin (OXA), raltitrexed (TOM), levo-folinic acid (LFA), and 5-fluorouracil (5-FU) during preoperative (preop) pelvic RT in high-risk locally advanced rectal cancer (HR-LARC) patients (pts)
Authors: A. Avallone, P. Delrio, E. Di Gennaro, B. Pecori, L. Aloi, F. Tatangelo, A. Petrillo, A. Budillon, C. Caracò, C. Sandomenico, P. Comella
Journal: Journal of Clinical Oncology (2009)

e14546 Background: OXA, RTX, 5FU, and LFA during preop pelvic RT produced a high rate of complete (TRG1) or subtotal (TRG2) tumor regression in HR-LARC. BEV might enhance response to chemoradiotherapy (CH-RT), but scheduling of BEV could be critical. Therefore, we added BEV to CH-RT in two different schedules to evaluate their feasibility and activity. According to the Simon's two-stage design, assuming a hypothesis of a 50% TRG1 (α=0.05, β=0.20), at least 6/16 TRG1 should be obtained to continue pts accrual in every schedule. Methods: Inclusion criteria were: cT4, cN+, cT3(&lt;5 cm from the anal verge and/or +ve CRM), resectable M1. Pts received 3 biweekly courses(c) of OXA (100 mg/m2)/TOM (2.5 mg/m2) on day 1, and 5FU (800 mg/m2)/LFA(250 mg/m2) on day 2 during pelvic RT (45 Gy). BEV (5 mg/kg) was given biweekly from day -14 for 4 c in schedule A, and from day -4 for 2 c in schedule B. Toxicity was graded with NCI-CTCv3. Changes of circulating endothelial cells (CECs)assessed by flow cytometry in 17 (7 A; 10 B) pts, and glucose metabolism evaluated by FDG-PET in 27 (15 A; 12 B) pts after 1st c of CT were used as surrogate markers of tumor response. The Mann-Whitney test assessed the differences in CECs and FDG-PET related to schedules. TME was planned 8 wks after CH- RT. Results: Until now, 28 pts (16 A; 12 B) were treated: M/F=19/9; median age 57 (range, 43–74) yrs. All but one pt (A) completed the planned CH-RT. Grade 3/4 neutropenia was the most common toxicity with schedule A (7 pts, 44%), while it never occurred with schedule B. No treatment-related or postop death occurred. CECs were more decreased by schedule B than by schedule A (median, -78% vs -29%, p&lt; 0.05). Glucose metabolism was also more reduced by schedule B (median, -78% vs -50%, p &lt; 0.05). All but one pt (refusal) of schedule A, and 7 pts of schedule B proceeded to TME. With schedule A, 2 pts obtained a TRG1, 8 pts a TRG2, 3 pts a TRG3 and 2 pts a TRG4. With schedule B, 4 pts obtained a TRG1 and 3 pts a TRG2. Conclusions: These data suggest the relevance of BEV scheduling during preop CT-RT to optimize safety and efficacy of the combination treatment. Updated results on the whole study population will be presented. No significant financial relationships to disclose.
Monoclonal B-Cell Lymphocytosis Exhibiting Immunophenotypic Features Consistent with Marginal Zone Origin: What Is This Entity?
Authors: Aliki Xochelli, Panagiotis Baliakas, Anne Gardiner, Sarah Mould, Zadie Davis, Neil McIver-Brown, Rachel Ibbotson, Evangelia Stalika, George Kanellis, Anastasia Athanasiadou, Achilles Anagnostopoulos, Theodora Papadaki, Kostas Stamatopoulos, David Oscier
Journal: Blood (2012)
Metastatic colorectal cancer patients who achieved long progression-free survival by regorafenib or TAS-102 therapy
Authors: Yosuke Kito, Satoshi Hamauchi, Kentaro Yamazaki, Azusa Komori, Toshiki Masuishi, Hiroya Taniguchi, Keita Mori, Kei Muro, Hirofumi Yasui
Journal: Annals of Oncology (2016)
Effect of probiotic treatment on the transition from chronic colonic inflammation to dysplasia and cancer.
Authors: C. B. Appleyard, M. L. Cruz, I. Passalacqua, A. A. Isidro, R. A. Isidro
Journal: Journal of Clinical Oncology (2011)

385 Background: Effective prevention of colitis-associated cancer still needs to be achieved. There is evidence that the microflora plays an important role in the progression of chronic inflammation to neoplastic transformation, so the aim of this study was to evaluate the potential efficacy of the probiotic VSL#3 in preventing this transition. Methods: Chronic colitis was induced in male Sprague Dawley rats by the administration of trinitrobenzene sulfonic acid (TNBS; 30 mg in 50% ethanol ic), followed six weeks later by reactivation with TNBS (5 mg/kg iv) for 3 days. To induce colitis-associated dysplasia and cancer the animals then received TNBS (iv) twice a week for ten weeks. One group of rats received the probiotic in drinking water (VSL#3; ∼5 billion cfu /100 gram body weight) from 1 week prior to initial colitis induction until the time of sacrifice (n = 22-23/group). After sacrifice the colons were removed and analyzed for total macroscopic damage, microscopic damage and presence of dysplasia or cancer. Tissue and serum samples were analyzed for cell proliferation and apoptosis, angiogenic factors and presence of alkaline sphingomyelinase. Results: Those animals receiving the probiotic had significantly less macroscopic and microscopic damage than the vehicle treated-controls in all areas of the colon (p &lt; 0.05). Pathological analysis revealed that 29% of the vehicle treated animals developed carcinoma, which was confined to the proximal region. None of the probiotic treated animals developed carcinoma. Treatment with the probiotic caused a significant shift to a less severe diagnosis with no high-grade dysplasia found in either the proximal or midcolon. Treatment with the probiotic reduced crypt cell proliferation by 22% as assessed by measurement of BrdU incorporation in comparison with the vehicle treated group. Levels of the antiangiogenic factor angiostatin were higher in the probiotic treated animals (5-fold), as were serum levels of alkaline sphingomyelinase (2-fold). Conclusions: Treatment with the probiotic VSL#3 can delay the transition of chronic inflammation to dysplasia and cancer via effects on processes such as modulation of cell proliferation and angiogenesis. No significant financial relationships to disclose.
Follicular Lymphoma: Design of a Protein-Based Survival Predictor Using Tissue-Microarrays (TMA).
Authors: Francisca I. Camacho, Reyes Arranz-Saez, Alessia Caleo, Jimena Cannata, Laura Cereceda, Leocricia Gonzalez, Mª Elena Perez-Martin, Lydia Sanchez-Verde, Carlos Montalban, Juan F. Garcia, Miguel A. Piris, Carmen Bellas
Journal: Blood (2004)
High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party
Authors: Gianantonio Rosti, Fausto Castagnetti, Angela Poerio, Massimo Breccia, Luciano Levato, Adele Capucci, Mario Tiribelli, Fabio Stagno, Alfonso Zaccaria, Tamara Intermesoli, Bruno Martino, Monica Bocchia, Michele Cedrone, Francesco Bartucci, Francesca Palandri, Gabriele Gugliotta, Nicoletta Testoni, Giuliana Alimena, Giovanni Martinelli, Fabrizio Pane, Giuseppe Saglio, Michele Baccarani
Journal: Blood (2008)
Epigenetic Silencing of BRCA1 Is Linked to Homologous Recombination Repair Defects and Elevated Mir-155 Expression in Myeloid Neoplasms
Authors: Weijie Poh, Alison R Moliterno, Keith W. Pratz, Ivana Gojo, Michael A McDevitt, James G. Herman
Journal: Blood (2014)
Knowledge of pain management in patients with painful bone metastases; A multicentre randomized trial on pain education
Authors: J.I. Geerling, A. Reyners, Y. van der Linden, V. Mul, P. Westhoff, A. de Graeff, C. Rodenhuis, E. de Nijs, T. Muilenburg
Journal: Annals of Oncology (2016)
Brain metastasis in advanced colorectal cancer: Results from the South Australian metastatic colorectal cancer (SAmCRC) registry
Authors: T.J. Price, C. Karapetis, C. Piantadosi, G. Tapia Rico, R. Padbury, G. Maddern, J. Moore, S. Carruthers, D. Roder, A.R. Townsend
Journal: Annals of Oncology (2016)
CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations
Authors: Supot Nimanong, Dmitrij Ostroumov, Jessica Wingerath, Sarah Knocke, Norman Woller, Engin Gürlevik, Christine S. Falk, Michael P. Manns, Florian Kühnel, Thomas C. Wirth
Journal: Cancer Research (2017)

Antagonistic antibodies targeting coinhibitory receptors have revolutionized the treatment of cancer by inducing durable immune responses and clinical remissions in patients. In contrast, success of agonistic costimulatory antibodies has thus far been limited because of the insufficient induction of adaptive immune responses. Here, we describe a novel vaccination method consisting of a primary dendritic cell (DC) immunization followed by a composite vaccination, including an agonistic CD40 antibody, soluble antigen, and a TLR3 agonist, referred to as CoAT. In mice, DC/CoAT prime-boost vaccinations targeting either MHC class I or II neoantigens or tumor-associated antigens rendered up to 60% of the total T-cell population specific for a single tumor epitope. DC/CoAT induced durable and complete remissions of large subcutaneous tumors without detectable side effects. Thus, booster vaccinations with agonistic costimulatory antibodies represent an ideal means to amplify DC vaccinations and induce robust T-cell immune responses while providing maximum flexibility regarding the choice of antigen. Cancer Res; 77(8); 1918-26. ©2017 AACR.
Consolidative Chemotherapy in Head & Neck Squamous Cell Carcinoma With Residual Disease After Definitive Chemoradiation
Authors: Teeranuch Chureemas, Jitlada Juengsamarn, Chuleeporn Jiarpinitnun, Thanit Layangkool, Phichai Chansriwong, Poompis Pattaranutaporn, Nuttapong Ngamphaiboon
Journal: Annals of Oncology (2016)
Genetic and Pharmacologic Inhibition of PKCθ and PKCα Prevents Acute Gvhd While Sparing GVL Activity in Mice.
Authors: Kelley M.K. Haarberg, Kane Kaosaard, Jun Li, Jessica Heinrichs, Crystina Bronk, Alexander M Owyang, Esteban Masuda, Claudio Anasetti, Amer Beg, Xue-Zhong Yu
Journal: Blood (2012)
An institutional universal standardized tobacco use assessment and intervention in cancer patients.
Authors: K. M. Cummings, A. Hyland, M. Zevon, M. Kelly, M. A. Long, T. L. Demmy, E. Dexter, R. Reed, J. Epstein, T. Houston, D. Jenkins, M. Mahoney, R. O'Connor, J. R. Marshall, M. E. Reid, J. L. Smith, M. Chmura, G. W. Warren
Journal: Journal of Clinical Oncology (2011)

e16543 Background: American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) Guidelines recommend that oncology patients be routinely screened for tobacco use, advised to quit, and offered assistance to quit. Unfortunately, the effectiveness of these guidelines has not been established in overall cancer populations primarily due to a failure to both develop and implement efficient standardized tobacco assessment and cessation procedures in comprehensive cancer treatment populations. Methods: A standard set of tobacco assessment questions was developed using evidence-based medicine and annotated using fixed-response variables (FRV). A logic based electronic medical record (EMR) referral system was developed to determine patient eligibility for referral to a dedicated tobacco Cessation Service. A clinical program was developed to provide standardized assessments for patients at initial presentation to an institution as well as at follow-up presentation during cancer treatment and follow-up. Results: At Roswell Park Cancer Institute, a working screening and referral algorithm was developed addressing: 1) maintenance of efficient clinical workflow, 2) capture of cancer patients at diagnosis, during treatment, and at follow-up, 3) real time EMR based data acquisition with FRV and automatic cessation service referral logic, and 4) design and implementation of a dedicated cessation service. The standardized assessment instrument, FRV, referral decision alogorithm, and cessation service clinical management structure will be presented. Early evaluation of the program demonstrates approximately 50% of current tobacco use patients are receptive for referral to the cessation service. Conclusions: An institution wide clinically efficient universal EMR based tobacco assessment and cessation service is feasible and patients are receptive to intervention as a clinical standard of care.
Prospective analysis of prostate cancer (PC) circulating tumor cells (CTCs) to predict response to docetaxel (DOC) chemotherapy.
Authors: David M. Nanus, Matthew Loftus, Naveed Hassan Akhtar, Scott T. Tagawa, Himisha Beltran, Oscar B. Goodman, Xi Kathy Zhou, Neil Harrison Bander, Paraskevi Giannakakou
Journal: Journal of Clinical Oncology (2012)

100 Background: Taxane chemotherapy induces cellular microtubule stabilization (bundling) leading to mitotic arrest and apoptotic cell death. We recently reported that in castration-resistant PC, stabilizing of microtubules by taxanes inhibits ligand-induced androgen receptor (AR) nuclear translocation and activation of ARE-gene transcription (Cancer Res 2011;71:6019). This suggests the clinical activity of DOC results from inhibition of AR signaling. A pilot analysis of CTCs from 14 CRPC pts receiving taxanes revealed that predominant cytoplasmic AR and decreased total AR intensity each was associated with increased odds of response (P&lt;0.001). We initiated a prospective trial to determine if CTC analysis could predict DOC response. Methods: Eligibility: Patients (pts) receiving DOC q21 days for CRPC with &gt;5 CTCs determined by CellSearch. On cycle 1 d1 + d8, CTCs are isolated by ficoll tube separation and by CellSearch enrichment. Cells are stained for expression of prostate specific membrane antigen (PSMA), CD45, AR and acetylated tubulin (AcTub) as a marker of microtubule stabilization. AR localization and total fluorescence intensity, and AcTub intensity are quantitated by confocal microscopy and correlated with response to DOC using PCWG2 criteria. 72 pts are planned to provide 80% power to detect an association. Results: 28 of 72 pts have been prospectively enrolled to assess AR and AcTub as a biomarker of response. 20 pts have discontinued DOC. Day 1 samples were obtained from 27 pts and day 8 on 22 (5 pts on days 9 to 21). Immunofluorescence staining and evaluation of PSMA, CD45, and acetylated tubulin was performed successfully in 8 pts analyzed to date. CTCs can be identified in all pts. Cells are scored for AR and AcTub intensity (scale 1- 4) and AR nuclear vs cytoplasmic localization. Conclusions: Our results to date indicate that PC CTCs can be readily isolated from men receiving DOC chemotherapy in a multicenter fashion and assayed for AR localization and AcTub. Preliminary results suggest that monitoring AR subcellular localization and microtubule bundling in CTCs may predict clinical responses to DOC chemotherapy, warranting further study, including our prospective trial.
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Authors: S.S. Neelapu, F.L. Locke, N.L. Bartlett, T. Siddiqi, I. Braunschweig, L.J. Lekakis, A. Goy, J. Castro, O. Oluwole, D. Miklos, J. Timmerman, C. Jacobson, P.M. Reagan, I. Flinn, U. Farooq, P. Stiff, L. Navale, M. Elias, J. Wiezorek, W.Y. Go
Journal: Annals of Oncology (2016)
The effectiveness of neoadjuvant chemotherapy with recombinant tumor necrosis factor-thymosin-&amp;agr;1in locally advanced breast cancer and effect on tumor angiogenesis
Authors: L. Vladimirova, N. Podzorova, E. Nepomnyaschaya, I. Novikova, E. Ulyanova, G. Zakora, E. Bondarenko
Journal: Annals of Oncology (2016)
Management of a migrated and embedded lumen-apposing metal stent: a solution to an emerging conundrum
Authors: Divyesh Sejpal, Peter Stein, Sumant Inamdar, Arvind Trindade
Journal: Endoscopy (2017)

A 38-year-old woman with a history of alcohol-induced pancreatitis presented with abdominal pain secondary to a large pseudocyst. An initial computed tomography (CT) scan showed a 10-cm fluid collection in the head of the pancreas that was abutting the stomach ([Fig. 1]). An endoscopic ultrasound (EUS) was performed and the pseudocyst was drained with a lumen-apposing metal stent (LAMS). The patient's symptoms resolved and a subsequent magnetic resonance imaging (MRI) scan 6 weeks after placement of the LAMS showed complete resolution of the pseudocyst ([Fig. 2]).
Letter From the Chairmen of the Working Groups to the Deputy Director, National Cancer Institute
Authors: Lester Breslow, Louis B. Thomas, Arthur C. Upton
Journal: JNCI Journal of the National Cancer Institute (1977)

Letter From the Chairmen of the Working Groups to the Deputy Director, National Cancer Institute Get access Lester Breslow, Lester Breslow Chairman, Epidemiology-Biostatistics Working Group Search for other works by this author on: Oxford Academic PubMed Google Scholar Louis B. Thomas, Louis B. Thomas Chairman, Pathology Working Group Search for other works by this author on: Oxford Academic PubMed Google Scholar Arthur C. Upton Arthur C. Upton Chairman, Radiation Carcinogenesis Working Group Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 59, Issue 2, August 1977, Page 469, https://doi.org/10.1093/jnci/59.2.469 Published: 01 August 1977